Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

RNA Biotech Raises $604M in IPO

NASDAQ share price display

Moderna Therapeutics, a biotechnology enterprise developing therapies with synthetic RNA, issued its initial public stock offering, or IPO, on Thursday, raising more than $604 million. . . . → Read More: RNA Biotech Raises $604M in IPO

Synthetic DNA Company Raising $70 Million in IPO

NASDAQ share price display

A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering. . . . → Read More: Synthetic DNA Company Raising $70 Million in IPO

Cancer T-Cell Start-Up Gains $150 Million in IPO

NASDAQ share price display

A three year-old company developing treatments for cancer with engineered T-cells from the immune system raised $150 million in its initial public offering of common stock. . . . → Read More: Cancer T-Cell Start-Up Gains $150 Million in IPO

Multi-Drug Resistance Antibiotic Developer to Issue IPO

A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering. . . . → Read More: Multi-Drug Resistance Antibiotic Developer to Issue IPO

Cancer Gene Therapy Company Raises $85M in IPO

A developer of cancer immunotherapies that transfer gene treatments into patients with brain tumors is raising $85 million in its initial public stock offering. . . . → Read More: Cancer Gene Therapy Company Raises $85M in IPO

Medical Robotics Company Crowdfunding IPO

A medical robotics company spun-off from labs at MIT is issuing its initial public stock offering through equity crowdfunding, aiming to raise $15 million. . . . → Read More: Medical Robotics Company Crowdfunding IPO

Immunotherapy Biotech Raises $102 Million in IPO

A biotechnology company developing treatments for solid tumors, harnessing the body’s immune system, for cancer patients most likely to respond is raising $102 million in its initial public stock offering. . . . → Read More: Immunotherapy Biotech Raises $102 Million in IPO

Biopharm Company Raising $40 Million in IPO

Omeros Corporation, a biopharmaceutical company developing drugs that prevent inflammation in surgeries, is raising $40 million in its initial public stock offering. . . . → Read More: Biopharm Company Raising $40 Million in IPO

Immunotherapy Company Raises $70 Million in IPO

Selecta Biosciences, a biotechnology company developing treatments harnessing the immune system, is raising $70 million in its initial public offering. . . . → Read More: Immunotherapy Company Raises $70 Million in IPO

Genome-Editing Company Raises $108 Million in IPO

Artist depiction of Cas9 protein editing a gene (Jennifer Doudna, University of California – Berkeley)

6 May 2016. Intellia Therapeutics, a developer of therapies based on genome editing, issued its initial public stock offering, raising $108 million. The Cambridge, Massachusetts enterprise, less than 2 years old, issued 6 million shares priced at $18.00. At . . . → Read More: Genome-Editing Company Raises $108 Million in IPO